Neuroendocrine Carcinoma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The neuroendocrine carcinoma market reached a value of USD 1.4 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 2.7 Billion by 2035, exhibiting a growth rate (CAGR) of 6.3% during 2025-2035.

The neuroendocrine carcinoma market has been comprehensively analyzed in IMARC's new report titled "Neuroendocrine Carcinoma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Neuroendocrine carcinoma is a type of cancer originating from neuroendocrine cells, which are specialized cells that release hormones into the bloodstream. It can manifest with a variety of symptoms that depend on the location of the tumor and the hormones it secretes. Some of the common indications include abdominal pain, persistent cough or wheezing, changes in bowel movements, unexplained weight loss, flushing or redness of the skin, diarrhea, hormonal imbalances, palpable lumps or masses, fatigue, jaundice, etc. The diagnosis of neuroendocrine carcinoma involves a combination of clinical evaluation, imaging studies, histopathological analysis, and molecular testing. Initial assessment typically includes a thorough medical history, physical examination, and blood tests to evaluate hormone levels and overall health status. Various imaging techniques, such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) scans, etc., aid in locating the tumor, determining its size, and detecting metastases. Additionally, numerous molecular tests, including genetic profiling and assessment of specific biomarkers, may be conducted to guide treatment decisions and identify potential therapeutic targets.

The increasing incidences of specific genetic mutations or alterations that disrupt normal cell growth and division, thereby leading to the uncontrolled proliferation of neuroendocrine cells, are primarily driving the neuroendocrine carcinoma market. Furthermore, the rising prevalence of numerous associated risk factors, such as prolonged exposure to carcinogens, hormonal imbalances, chronic inflammation, etc., is acting as another significant growth-inducing factor. Additionally, the escalating application of embolization therapy to shrink the tumor and control symptoms is also creating a positive outlook for the market. This procedure involves blocking the blood supply to the tumor by injecting small particles or coils into the blood vessels that are feeding the tumor. Moreover, the emerging popularity of immune checkpoint inhibitors, including pembrolizumab and nivolumab, among patients with high tumor mutational burden or mismatch repair deficiency is further bolstering the market growth. Apart from this, the widespread adoption of multiparametric magnetic resonance imaging (MRI) techniques, such as diffusion-weighted imaging (DWI) and dynamic contrast-enhanced MRI (DCE-MRI), on account of their several associated benefits, including improved lesion identification, assessment of tumor aggressiveness, detection of metastases, etc., is expected to drive the neuroendocrine carcinoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the neuroendocrine carcinoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for neuroendocrine carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neuroendocrine carcinoma market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the neuroendocrine carcinoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Neuroendocrine carcinoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current neuroendocrine carcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Neuroendocrine carcinoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the Neuroendocrine carcinoma across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the Neuroendocrine carcinoma across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of incident cases (2019-2035) of Neuroendocrine carcinoma across the seven major markets?
• What is the number of incident cases (2019-2035) of Neuroendocrine carcinoma by age across the seven major markets?
• What is the number of incident cases (2019-2035) of Neuroendocrine carcinoma by gender across the seven major markets?
• What is the number of incident cases (2019-2035) of Neuroendocrine carcinoma by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with Neuroendocrine carcinoma across the seven major markets?
• What is the size of the Neuroendocrine carcinoma patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend Neuroendocrine carcinoma of?
• What will be the growth rate of patients across the seven major markets?

Neuroendocrine Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Neuroendocrine carcinoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Neuroendocrine carcinoma market?
• What are the key regulatory events related to the Neuroendocrine carcinoma market?
• What is the structure of clinical trial landscape by status related to the Neuroendocrine carcinoma market?
• What is the structure of clinical trial landscape by phase related to the Neuroendocrine carcinoma market?
• What is the structure of clinical trial landscape by route of administration related to the Neuroendocrine carcinoma market?